Led · Series A · Jul 2026

Founded in May 2024 and led by Artem Sokolov, Humanoid develops commercially scalable, safe, and universal humanoid robots intended for use in logistics, manufacturing, and factory automation. The company has publicly announced a $150 million first tranche of a Series A at a $1.2 billion pre-money valuation. Humanoid plans to raise an additional $80–$100 million to complete the round by September. The reporting does not disclose operating metrics such as revenue or users. No prior funding rounds or detailed use-of-proceeds were disclosed in the article. The company positions itself to pursue commercial-scale deployments in industrial settings.

Participated · Series A · Jun 2026

Focused Energy develops laser-based fusion technology and was founded in 2021 as a spin-off of Technical University Darmstadt. Headquartered in Darmstadt, the company also maintains offices in Berlin, Austin, and San Francisco. It positions itself as a world-leading laser fusion company and aims to translate scientific fusion advances into industrial value creation. The company recently raised $240 million in a Series A—the largest fully secured Series A in the fusion industry—to accelerate system development. Focused Energy plans to deploy the capital at the former RWE power plant site in Biblis, Hesse, using the site’s infrastructure and RWE’s expertise to establish a blueprint for industrial laser fusion. Leadership has stated this financing will help the company expand its lead in laser fusion and commit to long-term industrial implementation in Europe.

Led · Seed · May 2026

The Path builds an AI-driven therapy-plus-coaching app that offers 11 customizable virtual therapists and allows users to set preferences like directness. Its AI model is post-trained from open-source models and has scored 95 on the Vera-MH mental health safety benchmark, compared with roughly 65 for consumer chatbots. The founders—Anson Whitmer and Tyler Sheaffer—previously worked at Calm, and Tony Robbins later joined as a co-founder after the lead investor became involved. The app is currently free while it acquires users, and the company plans to charge $40 per month in the future. The Path emphasizes building a model optimized for therapeutic structure and safety rather than engagement-driven responses.

Participated · Series A · May 2026

Hark is an ambitious AI startup developing what it calls the world's most advanced personal intelligence platform. The company is building a suite of custom native hardware devices paired with end-to-end speech, text, and vision models and deeply personalized memory systems. The goal is to create an AI that thinks like you — and sometimes ahead of you — to offload mental workload and handle tasks autonomously. Unlike general-purpose AI tools, Hark's systems are multimodal, built from scratch, and designed to interact with the world the way humans do: listening, speaking, seeing, remembering, and taking action. Currently in beta, Hark envisions bringing this kind of super-intelligence to everyone, freeing people to focus on meaningful work, creativity, and the people they care about.

Led · Series A · May 2026

Gilgamesh Pharmaceuticals pursues discovery and development of improved neuropsychiatric drugs, using a platform that combines neural-circuit translational methods with AI and machine learning to optimize safety, efficacy and dosing. Its pipeline includes the ibogaine-analog GM-3009 (supported by a $14 million NIDA grant), the oral NMDAR antagonist GM-1020 (completed Phase 1 SAD/MAD and progressed into Phase 2), non-hallucinogenic neuroplasticity candidates now in IND-enabling stages, and projects targeting M1/M4 receptors. In August 2025 the company completed a strategic divestiture of clinical-stage candidate GM-2505 to AbbVie for up to $1.2 billion, and it has a separate AbbVie collaboration that included a $65 million upfront payment and up to $1.95 billion in option/ milestone payments plus royalties. The company assembled a leadership team with extensive CNS drug-development experience and intends to use recent financing to fund clinical and preclinical programs and continued discovery efforts. Gilgamesh was founded in 2019 by Jonathan Sporn and Andrew Kruegel.